159 related articles for article (PubMed ID: 21680196)
1. Circulating tumor cells in prostate cancer: a potential surrogate marker of survival.
Doyen J; Alix-Panabières C; Hofman P; Parks SK; Chamorey E; Naman H; Hannoun-Lévi JM
Crit Rev Oncol Hematol; 2012 Mar; 81(3):241-56. PubMed ID: 21680196
[TBL] [Abstract][Full Text] [Related]
2. Circulating Tumor Cells as a Marker for Progression-free Survival in Metastatic Castration-naïve Prostate Cancer.
Josefsson A; Linder A; Flondell Site D; Canesin G; Stiehm A; Anand A; Bjartell A; Damber JE; Welén K
Prostate; 2017 Jun; 77(8):849-858. PubMed ID: 28295408
[TBL] [Abstract][Full Text] [Related]
3. Detection of prostate-specific antigen- or prostate-specific membrane antigen-positive circulating cells in prostatic cancer patients: clinical implications.
Millon R; Jacqmin D; Muller D; Guillot J; Eber M; Abecassis J
Eur Urol; 1999 Oct; 36(4):278-85. PubMed ID: 10473985
[TBL] [Abstract][Full Text] [Related]
4. Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer.
Meyer CP; Pantel K; Tennstedt P; Stroelin P; Schlomm T; Heinzer H; Riethdorf S; Steuber T
Urol Oncol; 2016 May; 34(5):235.e11-6. PubMed ID: 26795608
[TBL] [Abstract][Full Text] [Related]
5. The Novel Association of Circulating Tumor Cells and Circulating Megakaryocytes with Prostate Cancer Prognosis.
Xu L; Mao X; Guo T; Chan PY; Shaw G; Hines J; Stankiewicz E; Wang Y; Oliver RTD; Ahmad AS; Berney D; Shamash J; Lu YJ
Clin Cancer Res; 2017 Sep; 23(17):5112-5122. PubMed ID: 28615267
[No Abstract] [Full Text] [Related]
6. Epithelial cell adhesion molecule-positive circulating tumor cells as predictive biomarker in patients with prostate cancer.
Amato RJ; Melnikova V; Zhang Y; Liu W; Saxena S; Shah PK; Jensen BT; Torres KE; Davis DW
Urology; 2013 Jun; 81(6):1303-7. PubMed ID: 23622774
[TBL] [Abstract][Full Text] [Related]
7. Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer.
Gonzales JC; Fink LM; Goodman OB; Symanowski JT; Vogelzang NJ; Ward DC
Clin Genitourin Cancer; 2011 Sep; 9(1):39-45. PubMed ID: 21723797
[TBL] [Abstract][Full Text] [Related]
8. Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer.
Cheng HH; Plets M; Li H; Higano CS; Tangen CM; Agarwal N; Vogelzang NJ; Hussain M; Thompson IM; Tewari M; Yu EY
Prostate; 2018 Feb; 78(2):121-127. PubMed ID: 29105802
[TBL] [Abstract][Full Text] [Related]
9. Detection of circulating tumor cells with CK20 RT-PCR is an independent negative prognostic marker in colon cancer patients - a prospective study.
Hinz S; Hendricks A; Wittig A; Schafmayer C; Tepel J; Kalthoff H; Becker T; Röder C
BMC Cancer; 2017 Jan; 17(1):53. PubMed ID: 28086834
[TBL] [Abstract][Full Text] [Related]
10. The Use of a New CellCollector to Isolate Circulating Tumor Cells from the Blood of Patients with Different Stages of Prostate Cancer and Clinical Outcomes - A Proof-of-Concept Study.
Theil G; Fischer K; Weber E; Medek R; Hoda R; Lücke K; Fornara P
PLoS One; 2016; 11(8):e0158354. PubMed ID: 27479125
[TBL] [Abstract][Full Text] [Related]
11. Reverse transcription-polymerase chain reaction detection of prostate-specific antigen, prostate-specific membrane antigen, and prostate stem cell antigen in one milliliter of peripheral blood: value for the staging of prostate cancer.
Hara N; Kasahara T; Kawasaki T; Bilim V; Obara K; Takahashi K; Tomita Y
Clin Cancer Res; 2002 Jun; 8(6):1794-9. PubMed ID: 12060619
[TBL] [Abstract][Full Text] [Related]
12. Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer.
Goodman OB; Symanowski JT; Loudyi A; Fink LM; Ward DC; Vogelzang NJ
Clin Genitourin Cancer; 2011 Sep; 9(1):31-8. PubMed ID: 21705286
[TBL] [Abstract][Full Text] [Related]
13. Quantitative RT-PCR analysis of PSA and prostate-specific membrane antigen mRNA to detect circulating tumor cells improves recurrence-free survival nomogram prediction after radical prostatectomy.
Yates DR; Rouprêt M; Drouin SJ; Comperat E; Ricci S; Lacave R; Sèbe P; Cancel-Tassin G; Bitker MO; Cussenot O
Prostate; 2012 Sep; 72(12):1382-8. PubMed ID: 22228175
[TBL] [Abstract][Full Text] [Related]
14. Circulating Tumor Cells in Biochemical Recurrence of Prostate Cancer.
Aragon-Ching JB; Siegel RS; Frazier H; Andrawis R; Hendricks F; Phillips M; Jarrett T; Guebre-Xabiher H; Patierno S; Simmens SJ
Clin Genitourin Cancer; 2015 Oct; 13(5):e341-5. PubMed ID: 25956468
[TBL] [Abstract][Full Text] [Related]
15. High detection rate of circulating tumor cells in blood of patients with prostate cancer using telomerase activity.
Fizazi K; Morat L; Chauveinc L; Prapotnich D; De Crevoisier R; Escudier B; Cathelineau X; Rozet F; Vallancien G; Sabatier L; Soria JC
Ann Oncol; 2007 Mar; 18(3):518-21. PubMed ID: 17322541
[TBL] [Abstract][Full Text] [Related]
16. Positive prostate-specific antigen circulating cells detected by reverse transcriptase-polymerase chain reaction does not imply the presence of prostatic micrometastases.
Thiounn N; Saporta F; Flam TA; Pages F; Zerbib M; Vieillefond A; Martin E; Debré B; Chevillard S
Urology; 1997 Aug; 50(2):245-50. PubMed ID: 9255296
[TBL] [Abstract][Full Text] [Related]
17. The significance of circulating tumor cells in prostate cancer patients undergoing adjuvant or salvage radiation therapy.
Lowes LE; Lock M; Rodrigues G; D'Souza D; Bauman G; Ahmad B; Venkatesan V; Allan AL; Sexton T
Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):358-64. PubMed ID: 26238233
[TBL] [Abstract][Full Text] [Related]
18. Combined nested RT-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in prostate cancer patients: correlation with pathological stage.
Grasso YZ; Gupta MK; Levin HS; Zippe CD; Klein EA
Cancer Res; 1998 Apr; 58(7):1456-9. PubMed ID: 9537248
[TBL] [Abstract][Full Text] [Related]
19. Disseminated tumor cells and their prognostic significance in nonmetastatic prostate cancer patients.
Lilleby W; Stensvold A; Mills IG; Nesland JM
Int J Cancer; 2013 Jul; 133(1):149-55. PubMed ID: 23280694
[TBL] [Abstract][Full Text] [Related]
20. Epithelial-to-mesenchymal transition leads to disease-stage differences in circulating tumor cell detection and metastasis in pre-clinical models of prostate cancer.
Lowes LE; Goodale D; Xia Y; Postenka C; Piaseczny MM; Paczkowski F; Allan AL
Oncotarget; 2016 Nov; 7(46):76125-76139. PubMed ID: 27764810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
